elisanicolini retweeted
Very important data from PARTNER-3 presented at #TCT2025 👇
At 7 years, the composite endpoint (death, MI, stroke, or rehospitalization) occurred in 34.6% with TAVR vs 37.2% with surgery (difference -2.6%; 95% CI, -9.0 to 3.7). No differences between the two groups in stroke, valve deterioration, endocarditis, and revascularization.
Perhaps the most informative figure ⬇️: the vital status sweep analysis.
After accounting for patients initially lost to follow-up but later confirmed dead, the apparent late excess mortality with TAVR disappeared, highlighting the critical value of complete follow-up ascertainment.
Overall, TAVR remains a very safe and effective option for low-risk patients with aortic stenosis at long-term follow-up.
@djc795 @PhilGenereuxMD @mirvatalasnag @PPibarot @tavrkapadia @kaulcsmc @Hragy @sbrugaletta @g_giustinoMD @SVRaoMD @DLBHATTMD @azeemlatib @DrPascalMeier @aakriti_15 @SripalBangalore @nadig_cardio @aymanka @drptca @drpkhazracardi1 @TCTMD @aayshacader @PedroMDMSc @Ortega_Paz @ThomPilgrim @DFCapodanno @PCRonline @HadyLichaaMD
At 7 years, the composite endpoint (death, MI, stroke, or rehospitalization) occurred in 34.6% with TAVR vs 37.2% with surgery (difference -2.6%; 95% CI, -9.0 to 3.7). No differences between the two groups in stroke, valve deterioration, endocarditis, and revascularization.
Perhaps the most informative figure ⬇️: the vital status sweep analysis.
After accounting for patients initially lost to follow-up but later confirmed dead, the apparent late excess mortality with TAVR disappeared, highlighting the critical value of complete follow-up ascertainment.
Overall, TAVR remains a very safe and effective option for low-risk patients with aortic stenosis at long-term follow-up.
@djc795 @PhilGenereuxMD @mirvatalasnag @PPibarot @tavrkapadia @kaulcsmc @Hragy @sbrugaletta @g_giustinoMD @SVRaoMD @DLBHATTMD @azeemlatib @DrPascalMeier @aakriti_15 @SripalBangalore @nadig_cardio @aymanka @drptca @drpkhazracardi1 @TCTMD @aayshacader @PedroMDMSc @Ortega_Paz @ThomPilgrim @DFCapodanno @PCRonline @HadyLichaaMD
Presented at #TCT2025:
In low-risk patients with severe aortic stenosis, transcatheter and surgical aortic-valve replacement had similar 7-year survival and valve durability outcomes, with no evidence of differences in composite end points. Full PARTNER 3 trial results: nej.md/4nieHfx
@CRFHeart
0
9
34
6,514
elisanicolini retweeted
📣Excited to share our new publication in @JACCJournals #JACCAdvances
"Beyond Parental Leave: Addressing Infertility, Pregnancy, and Postpartum Complications Among Cardiologists"
Thanks to #ACCWIC @gina_lundberg for allowing us platform to discuss these issues at #ACC2024
"Beyond Parental Leave: Addressing Infertility, Pregnancy, and Postpartum Complications Among Cardiologists"
Thanks to #ACCWIC @gina_lundberg for allowing us platform to discuss these issues at #ACC2024
2
16
39
3,340
elisanicolini retweeted
Very sad and unbelievable news today for our community. Great gentleman, elegant, kind, nice, excellent interventional Cardiologist and scientist. Ciao Michele RIP @sicigise @EAPCIPresident @PCRonline
43
33
240
elisanicolini retweeted
#proglide and #manta allow safely seal #TAVR access entry site so effectively that surgical access looks today unacceptable in the majority of pts. Yet, vascular complications continue to occur so that improvement in anatomy-based device selection is deserved. #TAVI
🔥 Just published in @ehjopen @escardio
In 9259 patients undergoing TAVR:
🔸MANTA ⬇️ bleedings and vascular complications
🔸ProGlide ⬇️ vascular complications in RCT/PM trials
🔸ProStar performed poorly compared to MANTA and ProGlide
🔖 Read here!
doi.org/10.1093/ehjope…
0
4
10
elisanicolini retweeted
Great cases discussions from studies to guidelines and #EAPCI expert consensus doc to finally real world practice in Italy with #pVAD at #GISE @CristinaAuri17 @ancona_b @elinico5 #carlobriguori #tommasopiva @sicigise
During the session Clinical Forum about "PERCUTANEOUS VENTRICULAR ASSIST DEVICES FOR HIGH-RISK INTERVENTIONS" our special guests presented 3 interesting clinical scenarios:
👉🏻 The role of unloading in STEMI;
👉🏻 High risk;
👉🏻 ACS and advance acute heart failure.
0
3
6
elisanicolini retweeted
In the IMP-IT registry, device-related complications rate after #Impella implantation was 25.6%, with cardiogenic shock being the strongest predictor. Device-related complication wasn't an independent predictor of 1y mortality.
🔗 pubmed.ncbi.nlm.nih.gov/34389852/
#FOAMcc #CardioTwitter
🔗 pubmed.ncbi.nlm.nih.gov/34389852/
#FOAMcc #CardioTwitter
0
7
7
elisanicolini retweeted
Aortic angulation and #TAVR outcomes. Self-expanding valve performance in horizontal aorta. Insight from the HORSE Registry @RodrigoEstvez1 @sbrugaletta @barbanti_marco @MuntaneCarol @DrArifK @xarmario @Espino_Antonio #AHAJournals ow.ly/sbwu50G7GcO
0
28
62
elisanicolini retweeted
Updated @MountSinaiHeart #TAVRCathAID with 3D animations of coronary access post #TAVR with S3 and Evolut. Congrats DrAnnapoornaKini, DrSaminSharma & Team. Free download here: Apple apps.apple.com/us/app/id14453…
Android play.google.com/store/apps/det…
WebApp CardiologyApps.com/TAVRcathAID/
Android play.google.com/store/apps/det…
WebApp CardiologyApps.com/TAVRcathAID/
2
16
32
elisanicolini retweeted
On line on @CCIJournal our subanalysis from IMP IT Registry on impact on outcomes of timing of Impella implantation @sicigise @G_Tarantini01 @BURZOTTA_F @giuliamasiero3
0
10
34
elisanicolini retweeted
2/3 Clear reductions in unstable angina and angina-free status w/revasc. No diff in HF or stroke. All-cause death nearly identical between groups, with tight CI (RR=0.99, 95% CI 0.90-1.09). Net results favor revascularization in stable ischemic heart disease.
2
30
84
elisanicolini retweeted
Clinical expert consensus document on the use of percutaneous left ventricular assist support devices during complex high-risk indicated PCI @shci_sec @spcardio @sicigise @foroic @oriolrodriguez5 @RaulmorenoMD sciencedirect.com/science/articl…
0
11
21
elisanicolini retweeted
I don't know where this "in between" lies, but, anyway:
"The old paradigm of ‘SAVR if possible, TAVI if necessary’ no longer holds. Equally valid might be a new paradigm; ‘TAVI if possible, SAVR if necessary’. The truth is probably somewhere in between."
academic.oup.com/eurheartj/arti…
"The old paradigm of ‘SAVR if possible, TAVI if necessary’ no longer holds. Equally valid might be a new paradigm; ‘TAVI if possible, SAVR if necessary’. The truth is probably somewhere in between."
academic.oup.com/eurheartj/arti…
2
12
38
elisanicolini retweeted
Final 5-yr ABSORB analysis. Increased risk of BVS vs Xience EES ends at 3 years (time of complete bioresorption)- thereafter event rates tended to be lower with BVS. If new gen scaffolds have comparable results to DES w/i 3 yrs, BVS might be preferred to DES for many CAD pts.
8
48
106
elisanicolini retweeted
"Observational Multicenter Registry of Patients Treated with IMPella Mechanical Circulatory Support Device in ITaly: The IMP-IT Registry" by Alaide Chieffo et al. #EAPCI bit.ly/344l2E1
0
5
10
elisanicolini retweeted
#TAVR for low risk patients approved by FDA today!
Recent NCD lowered requirement from 2 cardiac surgeon consults to just 1.
Should it be a requirement that a patient with aortic stenosis also see an interventional cardiologist to discuss TAVR option before having SAVR?
Recent NCD lowered requirement from 2 cardiac surgeon consults to just 1.
Should it be a requirement that a patient with aortic stenosis also see an interventional cardiologist to discuss TAVR option before having SAVR?
6
26
43
elisanicolini retweeted
¡¡¡Se acabó!!!! 16/8/2019 FDA Approves TAVR in Low-Risk Patients.
Risk stratification for TAVR treatment is becoming obsolete and heart teams will likely need to assess treatment options based on anatomical characteristics, concomitant risk factors, and also patient preference
Risk stratification for TAVR treatment is becoming obsolete and heart teams will likely need to assess treatment options based on anatomical characteristics, concomitant risk factors, and also patient preference
2
19
39